Search

Your search keyword '"Alsop, Kathryn"' showing total 211 results

Search Constraints

Start Over You searched for: Author "Alsop, Kathryn" Remove constraint Author: "Alsop, Kathryn"
211 results on '"Alsop, Kathryn"'

Search Results

1. Concurrent RB1 Loss and BRCA Deficiency Predicts Enhanced Immunologic Response and Long-term Survival in Tubo-ovarian High-grade Serous Carcinoma.

2. Multiomic analysis of homologous recombination-deficient end-stage high-grade serous ovarian cancer

3. The genomic and immune landscape of long-term survivors of high-grade serous ovarian cancer

9. Association of p16 expression with prognosis varies across ovarian carcinoma histotypes: an Ovarian Tumor Tissue Analysis consortium study.

10. Refined cut-off for TP53 immunohistochemistry improves prediction of TP53 mutation status in ovarian mucinous tumors: implications for outcome analyses

11. Risk Factors for Ovarian Cancer by BRCA Status: A Collaborative Case-Only Analysis.

12. Therapeutic options for mucinous ovarian carcinoma

13. PPM1D Mosaic Truncating Variants in Ovarian Cancer Cases May Be Treatment-Related Somatic Mutations

14. Germline Mutations in the BRIP1, BARD1, PALB2, and NBN Genes in Women With Ovarian Cancer.

15. Evolution of late-stage metastatic melanoma is dominated by aneuploidy and whole genome doubling

17. Contributors

18. Germline Mutation in BRCA1 or BRCA2 and Ten-Year Survival for Women Diagnosed with Epithelial Ovarian Cancer

20. Supplementary Table 18 from Nonequivalent Gene Expression and Copy Number Alterations in High-Grade Serous Ovarian Cancers with BRCA1 and BRCA2 Mutations

21. Supplementary Data from Integrated Genome-Wide DNA Copy Number and Expression Analysis Identifies Distinct Mechanisms of Primary Chemoresistance in Ovarian Carcinomas

22. Table S4 from Homologous Recombination DNA Repair Pathway Disruption and Retinoblastoma Protein Loss Are Associated with Exceptional Survival in High-Grade Serous Ovarian Cancer

23. Supplementary Figures 1 - 15 from Nonequivalent Gene Expression and Copy Number Alterations in High-Grade Serous Ovarian Cancers with BRCA1 and BRCA2 Mutations

24. Supplementary Data from Homologous Recombination DNA Repair Pathway Disruption and Retinoblastoma Protein Loss Are Associated with Exceptional Survival in High-Grade Serous Ovarian Cancer

25. Supplementary Figures 1 - 9 from Profiles of Genomic Instability in High-Grade Serous Ovarian Cancer Predict Treatment Outcome

26. Data from Integrated Genome-Wide DNA Copy Number and Expression Analysis Identifies Distinct Mechanisms of Primary Chemoresistance in Ovarian Carcinomas

27. Supplementary Tables 4 - 8 from Profiles of Genomic Instability in High-Grade Serous Ovarian Cancer Predict Treatment Outcome

28. Supplementary Methods and Tables 1 - 15, 19 from Nonequivalent Gene Expression and Copy Number Alterations in High-Grade Serous Ovarian Cancers with BRCA1 and BRCA2 Mutations

29. Supplementary Tables 1 - 3 from Profiles of Genomic Instability in High-Grade Serous Ovarian Cancer Predict Treatment Outcome

31. A deep learning system accurately classifies primary and metastatic cancers using passenger mutation patterns

32. Combined burden and functional impact tests for cancer driver discovery using DriverPower

33. Integrative pathway enrichment analysis of multivariate omics data

34. Pathway and network analysis of more than 2500 whole cancer genomes

35. Divergent mutational processes distinguish hypoxic and normoxic tumours

36. Genomic footprints of activated telomere maintenance mechanisms in cancer

37. The molecular origin and taxonomy of mucinous ovarian carcinoma

39. BRCA1 and BRCA2 carriers with breast, ovarian and prostate cancer demonstrate a different pattern of metastatic disease compared with non‐carriers: results from a rapid autopsy programme.

40. Synthetic lethality between CCNE1 amplification and loss of BRCA1

41. Methylation of all BRCA1 copies predicts response to the PARP inhibitor rucaparib in ovarian carcinoma

42. Germline BRCA variants, lifestyle and ovarian cancer survival

44. Whole–genome characterization of chemoresistant ovarian cancer

46. Molecular correlates of platinum response in human high-grade serous ovarian cancer patient-derived xenografts

47. The Subclonal Architecture of Metastatic Breast Cancer: Results from a Prospective Community-Based Rapid Autopsy Program 'CASCADE'

48. Tandem duplication of chromosomal segments is common in ovarian and breast cancer genomes

49. Abstract IA05: Molecular analysis of exceptional response in high-grade serous ovarian cancer

50. Abstract A65: Spatial characterization of drug resistance in ovarian cancer

Catalog

Books, media, physical & digital resources